Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TIVC
stocks logo

TIVC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q2
1.13M
+601.86%
-102.000
+1357.14%
Estimates Revision
Stock Price
Go Down
down Image
-30.61%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Tivic Health Systems Inc (TIVC.O) is 0.00, compared to its 5-year average forward P/E of -0.57. For a more detailed relative valuation and DCF analysis to assess Tivic Health Systems Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.57
Current PE
0.00
Overvalued PE
0.25
Undervalued PE
-1.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.28
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.28
Undervalued EV/EBITDA
-0.84

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.11
Current PS
0.00
Overvalued PS
5.00
Undervalued PS
-0.77
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

TIVC News & Events

Events Timeline

(ET)
2025-11-13
08:45:31
Tivic Health Shares Results from Clinical Optimization Study of ncVNS
select
2025-11-10 (ET)
2025-11-10
09:16:34
Tivic Submits Patent Applications for Cancer Treatment and Nerve Stimulation Technology
select
2025-08-20 (ET)
2025-08-20
08:38:27
Tivic Health Secures Two Investigational New Drug Applications from Statera
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
11-10Newsfilter
Tivic Grows Its Intellectual Property Assets

  • New Patent Applications: Tivic Health Systems has filed two patent applications, one for TLR5 agonists like Entolimod and Entolasta to enhance cancer therapy outcomes, and another for optimized specifications of a non-invasive vagus nerve stimulation device.

  • Potential Benefits for Cancer Patients: The TLR5 agonists may serve as adjunctive therapies to improve the effectiveness of immuno-oncology treatments for late-stage cancer patients who are often immunocompromised.

  • Focus on Intellectual Property and Partnerships: CEO Jennifer Ernst emphasized the importance of expanding their intellectual property rights to create new partnership opportunities and market potential for their product candidates.

  • Overview of Tivic's Therapeutics: Tivic Health utilizes both biopharmaceutical and bioelectronic systems to address unmet medical needs, with a focus on enhancing immune responses and developing non-invasive medical devices for various diseases.

[object Object]
Preview
3.0
11-06Newsfilter
Tivic Health Scheduled to Announce Third Quarter 2025 Financial Results on November 14th Through Conference Call and Webcast

  • Earnings Announcement: Tivic Health Systems, Inc. will report its third quarter results for 2025 on November 14, 2025, via a pre-recorded conference call and webcast.

  • Company Overview: Tivic Health focuses on immunotherapeutics, utilizing both biopharmaceutical and bioelectronic systems to address unmet medical needs, particularly through its lead drug candidate, Entolimod™.

  • Innovative Approaches: The company is developing a non-invasive medical device aimed at regulating neural pathways related to various diseases, with early trials indicating promising results.

  • Forward-Looking Statements: The press release includes forward-looking statements that carry risks and uncertainties, advising caution in reliance on these projections.

[object Object]
Preview
1.0
10-23Newsfilter
Tivic CEO Jennifer Ernst to Participate in Panel at Northwell Health Innovation Constellation Forum on October 23rd

  • Tivic Health Participation: Tivic Health's CEO, Jennifer Ernst, will participate in the Constellation Forum on October 23, discussing advancements in bioelectronic medicine alongside other industry leaders.

  • Panel Discussion Focus: The panel titled "Building a Big Tent" will address the need for collaboration across the healthcare ecosystem to enhance the adoption and impact of bioelectronic medicine.

  • About Bioelectronic Medicine: The 2025 program will spotlight bioelectronic medicine, which integrates device technology with patient care, aiming to overcome challenges and explore commercialization strategies.

  • Tivic Health's Innovations: Tivic Health is developing a dual platform that combines biopharmaceutical and bioelectronic systems to address unmet medical needs, including a lead drug candidate for acute radiation syndrome and a promising non-invasive medical device targeting neural pathways.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Tivic Health Systems Inc (TIVC) stock price today?

The current price of TIVC is 2.04 USD — it has increased 15.25 % in the last trading day.

arrow icon

What is Tivic Health Systems Inc (TIVC)'s business?

Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.

arrow icon

What is the price predicton of TIVC Stock?

Wall Street analysts forecast TIVC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TIVC is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Tivic Health Systems Inc (TIVC)'s revenue for the last quarter?

Tivic Health Systems Inc revenue for the last quarter amounts to 146.00K USD, increased 15.87 % YoY.

arrow icon

What is Tivic Health Systems Inc (TIVC)'s earnings per share (EPS) for the last quarter?

Tivic Health Systems Inc. EPS for the last quarter amounts to -1.97 USD, decreased -49.87 % YoY.

arrow icon

What changes have occurred in the market's expectations for Tivic Health Systems Inc (TIVC)'s fundamentals?

The market is revising No Change the revenue expectations for TIVC for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -30.61%.
arrow icon

How many employees does Tivic Health Systems Inc (TIVC). have?

Tivic Health Systems Inc (TIVC) has 7 emplpoyees as of December 05 2025.

arrow icon

What is Tivic Health Systems Inc (TIVC) market cap?

Today TIVC has the market capitalization of 3.55M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free